Nalbuphine ( DrugBank: Nalbuphine )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 85 | Idiopathic interstitial pneumonia | 2 |
85. Idiopathic interstitial pneumonia
Clinical trials : 598 / Drugs : 435 - (DrugBank : 116) / Drug target genes : 100 - Drug target pathways : 210
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04030026 (ClinicalTrials.gov) | August 8, 2019 | 11/7/2019 | A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough | Phase 2, Double-blind, Randomized, Placebo-controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis (IPF) With Nalbuphine ER Tablets for the Treatment of Cough | Nalbuphine;Idiopathic Pulmonary Fibrosis;Cough | Drug: Nalbuphine ER;Drug: Placebo oral tablet | Trevi Therapeutics | Parexel | Active, not recruiting | 18 Years | 80 Years | All | 60 | Phase 2 | United Kingdom |
| 2 | EUCTR2018-004744-31-GB (EUCTR) | 24/06/2019 | 05/03/2019 | Efficacy and Safety Study: Nalbuphine ER Tablets for the Treatment of Cough in Idiopathic Pulmonary Fibrosis | A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Two-Treatment, Two-Period Crossover Efficacy and Safety Study in Idiopathic Pulmonary Fibrosis With Nalbuphine ER Tablets for the Treatment of Cough - CANAL | Treatment of Cough in Idiopathic Pulmonary Fibrosis;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Product Name: Nalbuphine Extended-Realease (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE Product Name: Nalbuphine Extended-Release (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE Product Name: Nalbuphine Extended-Release (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE Product Name: Nalbuphine Extended-Release (ER) Tablets Product Code: TR0311 INN or Proposed INN: Nalbuphine Other descriptive name: NALBUPHINE HYDROCHLORIDE | Trevi Therapeutics, Inc. | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 60 | Phase 2 | United Kingdom |